Because CGRP strongly suppresses cytotoxic CD8+ T-cells and can also shape B cell activity, we tested the CGRP receptor antagonist BIBN4096, which significantly slowed tumor growth (Fig. 7G–H) and altered the phenotype of Pnoc-expressing B-cells. Here, CD8A is linked to neoplasm.